Hydnocarpus Pentandra Nanosuspension And In Vitro Anti Cancer Studies Against MCF7 Cell Line
DOI:
https://doi.org/10.52783/jns.v14.2746Keywords:
Hydnocarpus pentandra, nanosuspension, MCF-7 cell line, breast cancer, apoptosis, nanotechnology, in vitro anticancer activityAbstract
Hydnocarpus pentandra, a medicinal plant widely known for its bioactive compounds, has shown significant therapeutic potential in various disease treatments. In recent years, nanotechnology-based drug delivery systems have gained attention for enhancing the efficacy of plant-derived bioactive compounds. This study focuses on the formulation and evaluation of Hydnocarpus pentandra nanosuspension and its in vitro anticancer activity against the MCF-7 breast cancer cell line. The nanosuspension was prepared using an optimized nano-precipitation technique, ensuring high drug loading efficiency, stability, and enhanced bioavailability. Characterization of the nanosuspension was carried out through particle size analysis, zeta potential measurement, polydispersity index (PDI), and scanning electron microscopy (SEM) to determine its morphology, stability, and dispersibility. The anticancer potential of the Hydnocarpus pentandra nanosuspension was evaluated through MTT assay, which measures cell viability in response to different concentrations of the formulation. The results demonstrated a dose-dependent cytotoxic effect on MCF-7 cells, indicating significant anticancer activity. The nanosuspension exhibited improved cellular uptake and enhanced cytotoxicity compared to the crude extract, suggesting that the nanoformulation plays a crucial role in increasing the bioavailability of the active compounds. Additionally, fluorescence microscopy and flow cytometry studies were performed to analyze apoptosis induction and cell cycle arrest mechanisms. The findings suggest that Hydnocarpus pentandra nanosuspension effectively inhibits the proliferation of MCF-7 cells through apoptosis-mediated pathways. The enhanced solubility, targeted drug delivery, and improved therapeutic efficacy of the nanosuspension make it a promising candidate for breast cancer treatment. Furthermore, the study highlights the potential of nanotechnology-based phytomedicines in cancer therapy, providing a novel approach for drug development. Future research should focus on in vivo studies and mechanistic evaluations to establish the clinical applicability of Hydnocarpus pentandra nanosuspension in oncology.
Downloads
Metrics
References
Dubey R. Impact of Nanosuspension technology on drug discovery and development. Drug `Deliv Technol 2006; 6: 65-7.
Anupam Kumar Sachan and Ankita Gupta, A review on Nanotized Herbal Drugs,International Journal of Pharmaceutical sciences and Research, 2015; Vol. 6(3) : 961-970.
Thapa RK, Khan GM, Baral KP, Thapa P: Herbal Medicine Incorporated Nanoparticles: Advancements in Herbal Treatment. Asian Journal of Biomedical and pharmaceutical sciences 2013 ; 3(24) : 7-14.
Gupta VK, Karar PK, Ramesh S, Misra SP, Gupta A: Nanoparticle formulation for hydrophilic and hydrophobic drugs. International Journal of research in pharmaceutical sciences 2010; 1:163-69.
Agniespzka z. Wilezewska, Katarzyna Niemirowicz, Karolina H. Markiewicz, Halina car; Nanoparticles as drug delivery systems, Institute of Pharmacology polish academy of sciences; volume 64, 1020-1037.
Arias JL, Ruiz MA, Lopez-viota M, Delglado AV. Poly(alkylcyanoacrylate) colloidal particles as vehicles for anti-tumour drug delivery: a comparitive study. Colloids and Surfaces B: Biointerfaces, 2008; 62: 64-70.
Alvarez-Roman R, Naik A, Kalia Y N, Guy R H, Fessi H. Skin penetration and distribution of polymeric nanoparticles.J.controlled release, 2004; 99: 53-62.
Gilles ER, Frechet JMJ. Dendrimers and dendritic polymers in drug delivery. Drug Discovery Today, 2005; 10(1): 35-43.
R.S. Pan, c.wang, x. Zeng, Y. Wen, H. Wu, M. Feng Int.J. Pharm, Volume 420, 2011,PP. 206-215.
Muller, R.H, Mader K, and Gohla, S. 2000, Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art European Journal of Pharmaceutics and Biopharmaceutics, 50, 161-177.
P. Ekambaram, A. Abdul Hasan,Sathali and K.Priyanka, Solid lipid nanoparticles: A review, Department of Pharmaceutics, college of Pharmacy , Madurai Medical college, 2011.
Moussaoui N, Cansell M, Denizot A. Marinosomes, marine lipid based liposomes : physical characterization and potential application in cosmetics. Int J.Pharm.2002; 242(1-2) : 361-385.
Nicolau C., Legrand A., Grosse E., Liposomes as carriers for in vivo gene transfer and expression, Methods in enzymology, 1987, 149, 157-176.
Jones, M.C. and Leroux, J.C. 1999, Polymeric micelles – a new generation of colloidal drug carriers European Journal of Pharmaceutics and Biopharmaceutics, 48, 101-111.
Boudier, A, Ubert-Pouessel, A, Gerardin, C, Devoissele, J.M, and Begu, S.2009, pH-sensitive double-hydrophilic block copolymer micelles for biological applications, International Journal of Pharmaceutics, 379, 212-217.
Jones M-C, Leroux J-C. Polymeric micelles- a new generation of colloidal drug carriers. Eur. J. Pharm.Biopharm, 1999; 48(2) : 101-111.
Anupam Kumar Sachan and Ankita Gupta, A review on Nanotized Herbal Drugs, International Journal of Pharmaceutical sciences and Research, 2015; Vol. 6(3) : 961-970.
Zheng L, Song JF : Curcumin multi-wall carbon nanotubes modified glassy carbon electrode and its electrocatalytic activity towards oxidation of Hydrazine. Sensors and Actuators B : Chemical 2009; 135: 650-5.
Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicine: From toxicology to Pharmacology. Adv. Drug. Deli. Rev. 2006; 58: 1460-1470.
Weng J, Ren J : Luminescent quantum dots : a very attractive and promising tool in biomedicine. Current Medicinal Chemistry 2006; 13: 897-978.
Ankhi Maiti and sagarika Bhattacharya, Quantum dots and application in medical science, International Journal of chemistry and chemistry Engineering, 2013, Volume 3, pp. 37-42.
Eleonora Petryayeva, W. Russ Algar, and lgor L. Medintz, Quantum Dots in Bioanalysis: A Review of Applications Across Various Platforms for Fluorescence Spectroscopy and Imaging, 2013, Vol 67, Issue 3, pp.215-252.
Xiaohui Pu, Jin Sun, Mol Li and Zhonggui He. Formulation of Nanosuspension as a new approach for the delivery of poorly, current nanoscience. Bentham Science Publishers ltd. 2009; 5 : 417-427.
Banavath H. Sivarama RK, Tahir A, Sajid A, Pattnaik G, Nanosuspension : an attempt to enhance bioavailbility of poorly soluble drugs, International Journal of Pharmaceutical sciences and Research, 1(9), 2010, 1-11.
Swarbrick J, Boylan J , Encyclopedia of pharmaceutical technology, 2002 . 2nd Edition, Marcel Dekker: New York,
Chingunpituk J, Nanosuspension Technology for Drug Delivery, Walailak J Sci & Tech, 4(2), 2007, 139-153.
National nanotechnology initiative. available at http ; // www. Nano.gov/html/facts/ What is nano. Html.
Davuluri chandrababu, Hiren B. Patel, Hardik L, Mendapara jayakumar dimeshbhai, A Review on Pharmaceutical Nanotechnology , Asian Journal of Pharmacy and Life Science, 2012, 2(2), : 324-337.
Debjit bhowmik, Chiranjib, R. Margret chandira B. Jayakar, Role of Nanotechnology in novel drug delivery system, Journal of Pharmaceutical Science and Technology, 2009,Vol 1(1), 20-35.
Patravale B, Abhijith AD, Kulkarni RM, Nanosuspensions: a promising drug delivery strategy, Journal of Pharmacy and Pharmacology, 56, 2004, 827-840.
Prasanna L, Nanosuspension Technology : A Review, International Journal of Pharmacy and pharmaceutical sciences, 2(4), 2010, 35-40.
Xiaohui P, Jin S, Mo L, Zhonggui H, Formulation of Nanosuspensions as a New sapproach for the Delivery of poorly soluble Drugs, Current Nanosciences, 5, 2009, 417-427.
Mohanty S, Role of Nanosuspensions in Drug Delivery system, International Journal of research in pharmaceutical and Biomedical sciences, 1(2), 2010,41-66.
Xiaohui Pu, Jin Sun, Mol Li and Zhonggui He. Formulation of nanosuspension as a new approach for the delivery of poorly, current nanoscience. Bentham science publishers Itd. 2009; 5: 417-427.
Liversidge G G, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: absolute oral bioavailability of nanocrystalline danazoline beagle dog. Int j pharm. 1995; 125(1) : 91-97.
Peters K, Leitzke S, Diederichs je, Borner K, Hahn H, Muller R H, Ethlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection.J antimycrob chemoth. 2000.
Senthil Kumar C, Vedha Hari B N, Sharavanan S P, Subramanian N, Punitha S and Senthil Kumar V. Novel metronidazole nanosuspension as a controlled drug delivery system for anthelmintic activity. Journal of Pharmacy Research . Oct 2010:3(10).
Yadav G, Singh S. Nanosuspension: a promising drug delivery system. Pharmacophore. 2012; 3(5): 217-243.
Grau MJ, Kayser O, Muller RH. Nanosuspensions of poorly soluble drugs reproducibility of small-scale production. Int J Pharm. 2000; 196:155-7.
Agnihotri S M and Vavia P R. Diclofenac loaded biopolymeric nanosuspension for sophthalmic application. Nanomed. Nanotech. Biol.Med. 2009; 5:90-95.
Muller R H, Jacobs C and Kayer O. Nanosuspension for the formulation of poorly soluble drugs. In:F Nielloud, G Marti-Mesters(ed). Pharmaceutical emulsion and suspension. New York, Marcel Dekker.2000;p;383-407.).
Nanosuspension : a formulation approach poorl soluble and poorl biavailale drugs. In D.Wise (ED) Handbook of pharmaceutical controlled release technology. 17, 2000, 345-57.
Chowdar KPR, Madhavi BLR. Novel drug delivery technologies for insoluble drugs. Ind. Drugs. 42(9), 2005, 557-563.
Patravale B, Abhijith AD, and kulkarni RM, Nanosuspension: a promising drug deliver strategy. J. Pharm. Pharcol. 56, 2004, 827-40.
Cornelia MK, Rainer H, Muller. Drug nanocrstals of poorl soluble drugs produced high pressure homogenizations. Eur. J . Pharm. Biopharm 62, 2006, 3-16.
Kaer O. Nanosuspensions for the formulation of aphidicol into improve drug targeting effects against Leishmania infected macrophages. Int . J. Pharm. 196, 2000,253-56.
Krause KP, Kaser O, Mader K, Gust R, Muller RH. Heav metal contamination of nanosuspensions produced b high pressure homogenization. Int. J.Pharm. 196, 2000, 169-72.
Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenousl injectable chemicall stable aqueous Omeprazole formulation using nanosuspensions. Eur. J. Pharm. Biopharm. 58, 2004, 615-619.
Nanopure RM. Pure drug nanoparticles for the formulation of poorly soluble drug. New Drug. 54, 2001, 62-8.
Barret ER. Nanosuspension in drug delivery. Nat. Rev. 3, 2004, 785-96.
Wong JC, Doty MJ, Rebbeck CL. Microprecipitation method for preparing submicron suspensions. US Patent no.6: 2003, 607-784.
B. Senthilnathan, H. Ameerkhan, Aswini Sofia PI, M. Abirami, T. Bharath, T. Ajithkumar and A.Maheswaran, Review on various approaches on preparation, characterization and applications of polymeric nanoparticles, 2015, Volume 6, 645-663.
Dearns R. Atovaquone pharmaceutical composition. US 601880, 2000.
Irene P, Ruggero B, Ferdinando G. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutical sciences, European journal of pharmaceutical sciences 27, 2006, 299-310.
Hamsaraj K, shenoy VS, Murthy RR. Industrially Feasible Alternative Approaches in the Manufacture of solid Dispersion : A Technical Report, AAPS Pharm SciTech 7(4), 2006,87.
Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs : Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995 ; 125 : 91-7.
Chen Y, Liu J, Yang X, Xu H. Oleanolic acid nanosuspension : preparation, in vitro characterization and enhanced hepatoprotective effect. J Pharm. Pharmacol. 2005, 57 : 259-264.
Muller RH, Jacobs C. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002; 19: 189-94.
Setler P. London: IIR Limited Drug delivery system; 1999. Identifying new oral technologies to meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules.
Chen Y, Liu J, Yang X, Xu H. Oleanolic acid nanosuspension : preparation, in vitro characterization and enhanced hepatoprotective effect. J Pharm. Pharmacol. 2005, 57 : 259-264.
Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Moller RH, et al. Preparation of a clofazimine nanosuspensions for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection. J Antimicrob Chemother 2000 ; 45 : 77-83.
Jacobs C, Kayder O, Muller RH. Nanosuspensions as a new approach for the formulation of poorly soluble drug tarazepide. Int J Pharm 2000; 196 : 161-4.
Moschwitzer J, Achleitner G, Promper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology . Eur J Pharm Biopharm 2004; 58: 615-9.
Setler P. Identifying new oral technologies to meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules. IIR Limited, Drug delivery systems London : 1999.
Liversidge GC. Paper presented at the 23rd International Symposium of the Controlled Release Bioactive Materials Society. Workshop on Particulate Drug Delivery Systems; 1996.
Kayser O, Olbrich C, Yardley V, Kiderten AP, Croft SL. Formulation of amphotercin-B as nanosuspension for oral administration. Int J Pharm 2003 ; 254 : 73-5.
Chen Y, Liu J, Yang X, Zhao X, Xu H. Oleanolic acid nanosuspensions : Preparation, in vitro characterization and enhanced hepatoprotective effect. J Pharm Pharmacol 2005 ; 57 : 259-64.
Kocbek P, Baumgartner S, Kristi J . Preparation and evaluation of nanosuspensions for enhancing dissolution of poorly soluble drugs Int J Pharm 2006 ; 312 : 179-86.
Langutth P, Hanafy A, Frenzel D, Grenier P, Nhamias A , Ohilg T, et al. Nanosuspension formulation for low soluble drugs : Pharmacokinetics evaluation using spiranolactone as model compound . Drug Dev Ind Pharm 2005; 31: 319-29.
Muller RH, Jacobs C. Production and characterization of Budenoside nanosuspension for pulmonary administration. Pharm Res 2002; 19: 189-94.
Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and characterization of Eudragit retard nanosuspensions for the occular delivery of cloricromene. AAPS Pharmscitech 2006; 7: 27.
Chen Y, Liu J, Yang X, Zhao X, Xu H. Oleanolic acid nanosuspensions : Preparation, in vitro characterization and enhanced hepatoprotective effect. J Pharm Pharmacol 2005 ; 57 : 259-64.
Jacobs C, Kayder O, Muller RH. Nanosuspensions as a new approach for the formulation of poorly soluble drug tarazepide. Int J Pharm 2000; 196 : 161-4.
Kayser O, Lemke A, Hernandz, Trejo N. The impact of Nanobiotechnology on the development of new drug delivery systems. Current Pharm Biotech 2005;6: 3-5.
Shah T, Patel D, Hirani J, Amin AF. Nanosuspensions as a drug delivery systems- A comprehensive review. Drug Del Tech 2007; 7: 42-53.
Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchkne. D. Mucoadhesion of colloidal particulate systems in the gastrointestinal tract. Eur J Pharm Biopharm 1997; 44:25-31.
Kayser O. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: Research and applications. Int J Pharm 2001; 214: 83-5.
Vanitha Pudata, Subrahmanyan V and Jhansi K A short note on cancer, Journal of Carcinogenesis & Mutagenesis 2:128 doi : 10.4172/ 2157-2518, 2011.
Gibbs, W. Wayt. Untangling the roots of cancer. Scientific. 2003.
Medical surgical Nursing, 5 th Edition (2000), Lewis, Sharon ; Heitkemper, Margaret ; Dirksen, Shannon ; Mosby.
Cancer research in ICMR Achievements in Kinetics accessed at icmr. nic.in/cancer.pdf.
Robert a Weinberg. the biology of cancer. Chapter 2. Garland publishing.
American society of clinical oncology clinical cancer advances 2009; major research advances in cancer treatment, prevention and screening. accessed at www.cancer.net/patient/asco%20resources/research%20&%20meeting/cca-2009.pdf on July, 57-65.
Vanitha Pudata, Subrahmanyan V and Jhansi K A short note on cancer, Journal of Carcinogenesis & Mutagenesis 2:128 doi : 10.4172/ 2157-2518, 2011.
Cooper GM (2000) ‘’chapter 14 : The Eukaryotic cell cycle’’. The cell : a molecular approach, Washington, D.C : ASM Press . ISBN 0-87893 – 106-6.
Cancer facts and figures 2001: ( 2001) ; American Cancer Society.
American society of clinical oncology, clinical cancer advances 2010. asco’s annual report on progress against cancer. accessed at www.cancer.net/patient/publications %20 and %20 resources/clinical %20 advances/cca-2010.pdf on june 8, 2012.
A Journey into cancer’s causes, Wescott, Siobhan, (2001), Alaska Native Health Board.
Schneider, K. 2001. Counseling about cancer. Strategies for genetic counselling. 2d ed. New York: John Wiley % Sons. Excellent information on the causes of cancer, genetic tests for predisposition to cancer, ethics and genetic councelling.
Http://training.seer.cancer.gov/disease/cancer.
Teny David, K.V. George, HPTLC Analysis of the leaf Extract of Hydnocarpus Macrocarpa (Beddome) Warb, Journal of Pharmacognosy and Phytochemistry, 2014; 3(1) : 43-51
Van-Steenis CGGJ. (Ed). Flora Malesiana.Vol. 5, Noordhoff LTD, Netherlands, 1958.
Nayar TS, Beegum RR, Mohanan N, Rajkumar G. Flowering Plants of Kerala. Tropical Botanical Garden and Research Institute, Thiruvananthapuram, Kerala, 2006.
Balakrishnan NP In : Daniel P (Ed.). The Flora of Kerala. Vol. 1, Botanical Survey of India, Kolkata, 2005.
Mitra RL In: Sharma BD, Balakrishnan NP. Flora of India. Vol. 2, Botanical Survey of India, Calcutta, 1993.
Sasidharan N. Biodiversity documentataion for Kerala Part 6: Flowering Plants. Kerala Forest Research Institute, Peechi, Kerala, 2004.
Gamble JS. Flora of the Presidency of Madras. Bishen Singh Mahendra Pal Singh, Dehradun, 1915.
Hydnocarpus Pentandrus- Jangli Almond’’. Flowers of India. Net. Retrieved 2013-11-21.
SEA HandBook, 2009 by the Solvent Extractors’ Association Of India.
‘’Minor oil crops- Individual monographs (Allanblackia-Almond-Chaulmoogra-Cuphea spp-Jatropa curgas)’’. Fao.org.Retrieved 2013-11-21.
A Modern Herbal, Chaulmoogra’’. Botanical.com.Retrieved 2013-11-21.
Kalpesh s. Wagh, satish K. Patil, Anup K. Akarte, Dheeraj T. Baviskar , Nanosuspension. A new approach of Bioavailability enhancement, Department of Pharmaceutics, Institute of Pharmaceutical Education, Boradi, Volume 8, Issue 2, 2011, 61-65.
K. Bala Krishna, A review on nanosuspension in drug delivery, International Journal of Pharma and Bio Sciences, Vol 2, Issue 1, 2011, 549-558.
Vishal R. Patel and Y.K. Agarwal, Nanosuspension: An approach to enhance solubility of drugs, Journal of Advanced Pharmaceutical Technology & Research, Volume 2, Issue 2, 2011,81-87.
Mitesh Patel, Arpit Shah, Dr. N.M. Patel, Dr. M.R. Patel, Dr. K.R. Patel, Nanosuspension : A Novel approach for drug delivery system, Journal of pharmaceutical science and Bioscientific research, 2011, Volume 1, Issue 1, pg 1-10.
Geeta Vikram Yadhav and Sushma R. Singh, Nanosuspension: A Promising drug delivery system, An International Research Journal, Vol.3(5), 2012, 217-243.
Praun J.S. and Tank H.M, Nanosuspension: An emerging trend for bioavailability enhancement of poorly soluble drugs,Assian J.Pharm. Tech.Vol.2:Issue 4, 2012,Pg 157-168.
Sarita Kumari Yadav, Shivani Mishra and Brahmeshwar Mishra,Eudragit-Based Nanosuspension of poorly water-soluble drug formulation and in-vitro-in vivo evaluation,AAPS PharmSciTech,Vol 13(4),2012,Pg 1031-1044.
K. Masilamani and V.Ravichandran, Effect of formulation and process variables on drug content and entrapment efficiency of aceclofenac nanosuspension, International Research Journal of pharmacy, 2012, 3(3), pg 315-318.
Sutradhar, Kumar Bishwajit, Khatun, Sabera; Luna, Irin Praven,Increasing possibilities of Nanosuspension,Journal of Nanotechnology, 2013.
Arunkumar N, Deecarman M and Rani C. Nano Suspension technology and its application in drug delivery, Asian journal of Pharmaceutics,2013, Volume 3; issue 3, 168-173.
Ahlawat Priyanka, Diwan Anupama, Singh Robin, Nanosuspension: Recent trends and technologies, International Research Journal of Pharmacy, 2013, 4(7), pg 5-11.
Rupali L. Shid, Shashikant.N.Dhole, Nilesh Kulkarni, Santosh L.Shid, Nanosuspension: A review, Int J. Pharm. Sci, 2013, Volume 22, Issue 1,Pg 98-106.
Shanti Bhushan Mishra, Himanshu Pandey and Avinash C Pandey, Nanosuspension of Phyllanthus amarus extract for improving oral bioavailability and prevention of Paracetamol induced hepatotoxicity in Sprague- Dawley rats,Adv. Nat. Sci: Nanotechnol, 2013, Vol.4 Pg 1-6.
P.Amudha AND M.komala,Formulation of Nanosuspension drug delivery system containing coriander sativum extracts,International Journal of Biopharmaceutics,2014, Volume 5,Issue3,Pg 241-254.
Steffi PF and Srinivasan M, Preparation, Characterization and stabilization of Curcumin Nanosuspension, International Journal of PharmTech Research, 2014, Volume 6,No:2,Pg 842-849.
A.Abirami, Dr. S. Mohamed Halith, K.K. Pillai, Chithirra anbalagan, Herbal Nanoparticle for anticancer potential. A review, World Journal of pharmacy and pharmaceutical sciences, 2014, Volume 3, Issue 8, pg 2123-2132.
Roya Yadollahi, Krasimir Vasilev, and Spomenka , Simovic, Nanosuspension technologies for delivery of poorly soluble drugs, Journal of Nanomaterials, 2014 pages 13.
Samar A. Afifi, Maha A. Hassan, Ali S. Abdelhameed and Kadria A. Elkhodairy, Nanosuspension: An Emerging Trend for Bioavailability Enhancement of Etodolac, International Journal of Polymer science Volume 2015(2015), Article ID 938594, 16 Pages.
Zhiping Wang, Junbiao Wu, Qun Zhou, Yifei Wang, and Tongsheng Chen, Berberine Nanosuspension on Enhances Hypoglycemic efficacy on Streptozotocin Induced Diabetic C57BL/6 Mice, Volume 2015 (2015), Article ID 238749, 5 Pages.
Kiran Thadkala, Chintha Sailu and Jithan Aukunuru, Formulation, optimization and evaluation of oral nanosuspension tablets of nevibolo hydrochloride for enhancement of dissolution rate, 2015, 7 (3) : 71-84.
Nazish Jahan, saba Aslam, Khalil ur Rahman, Tuba Fazal, Fareeha Anwar and Rubab Saher, Formulation and characterization of nanosuspension of herbal extracts for enhanced antiradical potential, 2015.
Shanti Bhushan Mishra, Himanshu Pandey and Avinash C Pandey, Nanosuspension of Phyllanthus amarus extract for improving oral bioavailability and prevention of Paracetamol induced hepatotoxicity in Sprague- Dawley rats, Adv. Nat. Sci: Nanotechnology.2013, Vol.4 Pg 1-6.
D. Kozak, et al, (2011). Advances in resistive pulse sensors: Devices bridging the void between molecular and microscopic detection’’ Nano Today E. Van der Pol, et al. ‘’Optical and non-optical methods for detection and characterization of microparticles and exosomes’’ Journal of Thrombosis and Haemostatis (2010), 8: 2596-2607.
Guozhonq Cao, Nanostructures and Nanomaterials, synthesis, Properties and Applications, Publication 2004, Reprinted 2005, 2006, Imperial college press.
Ashutosh Kar, Text book of Pharmaceutical Drug Analysis, ISSBN (13), pg 293-321.
Hecq, M. Deleers, D. Fanara, H.Vrandex, K. Amighi,Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm, 2005, 299; 167-177.
He S, Yang H, Zhang R, Li Y, Duan L. Preparation and in vitro-in vivo evaluation of teniposide nanosuspensions, International Journal of Pharmaceutics, 2014; 478(1): 131-137.
Mohammed F A, Srinivas R A, Mohammed 1.Phytochemical studies and Antioxidant activity of Melia Azedarach Linn Leaves by DPPH Scavenging assay. International Journal of Pharmaceutical applications, 2013; 3(1) : 271.
Sharma D.K and Iris H. Hall, “ Hypolipidemic, anti-inflammatory, antineoplastic activity and cyto-toxicity of flavonoligans isolated from Hydnocarpus wightiana seeds”. Journal of Natural products., 1991, 54(5), 1298-1302.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
